对于心神经综合征的新型治疗点
Mansi Vinodkumar Trivedi1, Hemant R Jadhav1, Anil Bhanudas Gaikwad1
1Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan 333031, India.
Drug discovery today
|January 6, 2025
概括
心脏综合征涉及相互依赖的心脏和脏功能障碍. 由于当前心综合征治疗方法的局限性,新的治疗点至关重要.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 生物医学科学 生物医学科学
背景情况:
- 心脏病综合征 (CRS) 是一种复杂的疾病,其特点是心脏和脏的相互依存功能障碍.
- 病理生理机制包括氨酸- ангиотензин- алдостерон系统 (RAAS) 激活,炎症,纤维化和氧化应激,导致器官损伤.
研究的目的:
- 审查当前心综合征治疗方法的局限性.
- 突出在CRS管理中迫切需要新的治疗目标.
主要方法:
- 关于心脏脏综合征病原和治疗的文献综述.
- 识别和讨论新出现的治疗点.
主要成果:
- 目前用于心综合征的治疗方法,包括RAAS抑制剂和利尿剂,具有显著的局限性,例如利尿剂耐药性.
- 像Klotho,SOX9,RIPK3,BAIBA和TSP-1这样的新兴目标显示出在CRS.中新的治疗策略的潜力.
结论:
- 迫切需要创新的治疗方法来解决心脏脏综合征.
- 探索涉及CRS病变的新目标为改善患者治疗结果提供了有前途的途径.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Antihypertensive Drugs: Direct Renin Inhibitors
484
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
484
Hormonal Regulation
32.9K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
472
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
472


